drugset / Trial / NCT03288636

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

NCT03288636

Phase 1 Completed 18 enrolled Ascletis Pharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the Pharmacokinetics and Safety of single dose of Ravidasvir and Danoprevir/r and repeated doses of Ravidasvir in combination with Danoprevir/r in healthy volunteers.

Timeline

Start
2017-08-08
Primary completion
2017-09-14
Completion
2017-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravidasvir Small molecule 200 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Subject danoprevir Small molecule 100 mg Oral